KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Precigen (PGEN) Research & Development (2016 - 2025)

Historic Research & Development for Precigen (PGEN) over the last 14 years, with Q3 2025 value amounting to $12.4 million.

  • Precigen's Research & Development rose 885.66% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year decrease of 1510.88%. This contributed to the annual value of $53.1 million for FY2024, which is 916.61% up from last year.
  • Precigen's Research & Development amounted to $12.4 million in Q3 2025, which was up 885.66% from $11.5 million recorded in Q2 2025.
  • Precigen's 5-year Research & Development high stood at $15.7 million for Q2 2024, and its period low was $10.5 million during Q1 2025.
  • In the last 5 years, Precigen's Research & Development had a median value of $12.0 million in 2022 and averaged $12.2 million.
  • In the last 5 years, Precigen's Research & Development surged by 4403.31% in 2021 and then tumbled by 2679.54% in 2025.
  • Over the past 5 years, Precigen's Research & Development (Quarter) stood at $12.2 million in 2021, then dropped by 11.37% to $10.8 million in 2022, then increased by 20.39% to $13.0 million in 2023, then dropped by 9.51% to $11.8 million in 2024, then grew by 5.26% to $12.4 million in 2025.
  • Its Research & Development stands at $12.4 million for Q3 2025, versus $11.5 million for Q2 2025 and $10.5 million for Q1 2025.